Business Context and Reporting Period
Company: BioVie Inc. (BIVI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological/neurodegenerative disorders and advanced liver disease. The company has no approved products and has never generated revenue. Its primary assets are:
- Bezisterim (NE3107): An investigational oral small molecule for Alzheimer's Disease (AD), Parkinson's Disease (PD), and Long COVID.
- BIV201: A continuous infusion terlipressin formulation for ascites and complications of liver cirrhosis.
Key Financial Metrics
| Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17.5) million | $(32.1) million |
| Operating Expenses | $18.1 million | $32.2 million |
| Research & Development (R&D) | $9.3 million | $23.1 million |
| Selling, General & Administrative (SG&A) | $8.6 million | $8.8 million |
| Cash and Cash Equivalents | $17.5 million | $23.8 million |
| Working Capital | $18.4 million | $14.7 million |
| Stockholders' Equity | $19.0 million | $15.5 million |
| Accumulated Deficit | $(352.1) million | $(334.2) million |
| Debt | $0 (Notes payable paid in full Dec 2024) | $5.7 million (net) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $14.6 million (46%) compared to the prior year, primarily driven by a $13.8 million reduction in R&D expenses.
- R&D Expense Decline: R&D costs dropped from $23.1 million to $9.3 million. This was due to the completion of the pivotal Phase 3 Alzheimer's trial and other studies in the prior year, partially offset by the initiation of new Phase 2 studies for Parkinson's and Long COVID.
- Debt Repayment: The company fully repaid its $5 million note payable to Avenue Venture Opportunities Fund in December 2024, eliminating interest expense associated with that debt for the current period.
- Capital Raises: The company raised approximately $18.9 million in gross proceeds through registered direct offerings in September and October 2024.
- Reverse Stock Split: A 1-for-10 reverse stock split was effected on July 7, 2025, subsequent to the fiscal year-end.
Guidance, Outlook, Risks, and Unusual Items
Clinical Program Updates
- Alzheimer's Disease (AD): The Phase 3 trial (NCT04669028) was underpowered due to the exclusion of 15 study sites following significant protocol deviations and cGCP violations. While the trial did not meet primary endpoints, descriptive data in the Per-Protocol population suggested a slowing of cognitive decline and age deceleration. The company is considering adaptive trial features or a new Phase 3 design.
- Parkinson's Disease (PD): A new Phase 2b study (Sunrise PD) for new-onset PD commenced in April 2025.
- Long COVID: The Phase 2 ADDRESS-LC study, fully funded by a $13.1 million DOD grant, commenced in May 2025.
- Liver Disease (BIV201): The company is finalizing the Phase 3 protocol design for ascites, focusing on patients who have recently recovered from acute kidney injury.
Risks and Contingencies
- Going Concern: The company has incurred recurring losses and negative cash flows. Management states there is substantial doubt about the company's ability to continue as a going concern without additional financing.
- Legal Proceedings: The company is subject to a consolidated securities class action lawsuit (In re BioVie Inc. Securities Litigation) regarding the Phase 3 AD trial. The court denied the motion to dismiss in March 2025, and discovery is underway. Two shareholder derivative lawsuits are also pending. The company has a $2 million deductible on its insurance coverage for these claims.
- Capital Needs: The company expects to require substantial additional capital to fund operations and clinical trials. Future funding may come from equity offerings, debt, or strategic transactions.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to assess the timeline before additional capital is required, given the "substantial doubt" going concern warning.
- Legal Exposure: Monitor the status of the securities class action and derivative lawsuits, specifically the potential liability exceeding the $2 million insurance deductible.
- Alzheimer's Trial Path: Confirm the FDA's response to the company's proposed next steps for the underpowered Phase 3 AD trial (adaptive enrollment vs. new study design).
- Dilution Risk: Review the terms of recent and potential future equity offerings, noting the significant number of outstanding warrants (960,098) and options (84,872) that could dilute shareholders.
- Grant Utilization: Track the utilization of the $13.1 million DOD grant for the Long COVID study to ensure it covers the projected costs of the Phase 2 trial.